抗HIV治療ガイドライン（2024年3月発行）

XVI医療従事者におけるHIVの曝露対策

文献

  1. Bell DM: Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview. Am J Med. 102 (Suppl. 5B): 9-15, 1997.
  2. Ippolito G, Puro V, De Carli G. The risk of occupational human immunodeficiency virus infection in health care workers. Arch Intern Med. 153: 1451-8, 1993.
  3. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 341(6):385-93.1999.
  4. Recommendations for the Use of Antiretroviral Drugs during Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States (Last updated Jan. 31,2024). https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new
  5. Rodriguez MG, Syros A, Rodriguez AE, Serota DP. The Perils of Overly Sensitive Viral Load Testing for Persons With Human Immunodeficiency Virus. Open Forum Infect Dis. 2023 Oct 3;10(10):ofad494.
  6. Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet. 2023 Aug 5;402(10400):464-471.
  7. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 34(9):875-92. 2013.
  8. Expert Advisory Group on AIDS. Providing expert scientific advice on HIV. Updated recommendation for HIV post-exposure prophylaxis (PEP) following occupational exposure to a source with undetectable HIV viral load.
    https://www.gov.uk/government/publications/eaga-guidance-on-hiv-post-exposure-prophylaxis
  9. Young TN, Arens FJ, Kennedy GE, et al. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. (1):CD002835. 2007.
  10. 平成5年7月13日付　厚生省保健医療局エイズ結核感染症課長（健医感発 第78号） https://api-net.jfap.or.jp/library/data/law/doc_02_23.htm
  11. 労災保険におけるHIV感染症の取扱いについて(通知)、厚生労働省健康局疾病対策課長通知(健疾発0909第1号)、平成22年9月9日 https://www.mhlw.go.jp/web/t_doc?dataId=00tb6414&dataType=1&pageNo=1
  12. C型肝炎、エイズ及びMRSA感染症に係る労災保険における取扱いについて、厚生労働省労働基準局長通知(基発第619号)、平成5年10月29日 https://www.mhlw.go.jp/web/t_doc?dataId=00tc6698&dataType=1&pageNo=1
  13. New York State Department of Health AIDS Institute. Clinical guidelines program. Post-Exposure Prophylaxis (PEP) to Prevent HIV infection. (Last reviewed and updated (Apr 17, 2023) https://www.hivguidelines.org/collection/pep-prep/#tab_2
  14. HIV post-exposure prophylaxis. Guidance from the UK Chief Medical Officers’ Expert Advisory Group on AIDS. Department of Health, 2008.
    https://www.gov.uk/government/publications/eaga-guidance-on-hiv-post-exposure-prophylaxis
  15. Eye of the Needle. United Kingdom Surveillance of Significant Occupational Exposures to Bloodborne Viruses in Healthcare Workers. Public Health England. December 2014. https://www.gov.uk/government/publications/bloodborne-viruses-eye-of-the-needle
  16. Mayer KH, Molina JM, Thompson MA, Anderson PL, Mounzer KC, De Wet JJ, DeJesus E, Jessen H, Grant RM, Ruane PJ, Wong P, Ebrahimi R, Zhong L, Mathias A, Callebaut C, Collins SE, Das M, McCallister S, Brainard DM, Brinson C, Clarke A, Coll P, Post FA, Hare CB. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020 Jul 25;396(10246):239-254.
  17. Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 397:1276-1292, 2021.
  18. European AIDS Clinical Society (EACS) Guidelines. Version 12.0-October 2023. https://eacs.sanfordguide.com
  19. Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med.379(10):979-81. 2018.
  20. Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019 Aug 29;381:827-840.
  21. Zash R, Holmes L, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. 23rd International AIDS Conference 2020. #OAXLB0102.
  22. de Boer MG, van den Berk GE, van Holten N, et al. Intolerance of dolutegravir containing cART regimens in real life clinical practice. AIDS. 30(18):2831-4, 2016.
  23. 関根祐介、平野智理、冨樫英晶、他. 東京医科大学におけるドルテグラビルの使用状況と有害事象について.
    2015年　第29回日本エイズ学会学術集会（東京）、抄録番号O7-035.
  24. HRD共同調査協議会. HIV感染症治療薬共同使用成績調査2018年報告書（1997年8月〜2018年3月31日）
  25. 薬剤耐性インフォメーションセンター、https://www.hiv-resistance.jp/research03.htm
  26. Mayer KH, Gelman M, Holmes J, et al. Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure. C J Acquir Immune Defic Syndr May 1;90(1):27-32. 2022.
  27. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. N. Engl. J. Med. 337: 1485-90, 1997.
  28. Notes from the Field: Occupationally Acquired HIV Infection Among Health Care Workers-United States, 1985-2013. MMWR January 9, 2015.

PAGE TOP